Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 8.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 699,814 shares of the company's stock after purchasing an additional 55,051 shares during the quarter. Wellington Management Group LLP owned 0.69% of Intellia Therapeutics worth $8,160,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. ARK Investment Management LLC increased its position in shares of Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock valued at $146,174,000 after purchasing an additional 280,946 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Intellia Therapeutics by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock valued at $118,816,000 after acquiring an additional 562,249 shares during the period. State Street Corp lifted its holdings in shares of Intellia Therapeutics by 17.9% in the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after acquiring an additional 780,754 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in shares of Intellia Therapeutics during the 4th quarter worth about $43,177,000. Finally, Geode Capital Management LLC raised its position in Intellia Therapeutics by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company's stock worth $48,164,000 after purchasing an additional 49,367 shares during the period. Institutional investors own 88.77% of the company's stock.

Wall Street Analysts Forecast Growth

NTLA has been the topic of several recent analyst reports. The Goldman Sachs Group reiterated a "sell" rating and issued a $9.00 price target on shares of Intellia Therapeutics in a report on Friday, February 28th. Barclays lowered their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a report on Friday, February 28th. HC Wainwright assumed coverage on Intellia Therapeutics in a report on Wednesday, March 5th. They issued a "buy" rating and a $30.00 target price for the company. JPMorgan Chase & Co. restated a "neutral" rating and issued a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Finally, Wells Fargo & Company dropped their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.56.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock traded down $0.39 during midday trading on Wednesday, reaching $6.97. 486,896 shares of the company were exchanged, compared to its average volume of 2,320,361. The firm's 50-day simple moving average is $9.03 and its 200-day simple moving average is $12.41. The company has a market capitalization of $721.20 million, a price-to-earnings ratio of -1.28 and a beta of 2.23. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.18.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.